Biopharm Reports publishes new market findings on current practices, developments, trends, growth, shrinkage and opportunities in the cancer molecular diagnostics field, which includes research into Circulating Tumour Cells (CTCs) and Cancer Stem Cells (CSCs) in diagnostics.
The study of Circulating Tumour Cells and Cancer Stem Cells are two of the most rapidly growing areas in cancer diagnostics
Online PR News – 26-January-2014 – London – Circulating Tumour Cells (CTCs) are cancer cells that are shed from tumours into the vasculature and are found in the bloodstream. CTCs therefore represent a mobile population of cancer cells, and are believed to have the ability to seed the growth of new tumours in the body at sites distant from the tumour of origin. Cancer Stem Cells (CSCs) are cancer cells that have stem cell properties, notably in their ability to give rise to different cell types in tumours. Scientists describe CSCs are tumuorigenic (tumour-forming), as distinct from other cancer cells that are described as non-tumorigenic. As such, CSCs are reported to represent distinct populations of cancer cells in tumours, which through their 'stem-like' properties are able to self-renew and differentiate into multiple cancer cell types in an hierarchical manner. There is evidence that CSCs represent unique subpopulations of CTCs, and CSCs have recently been described as Circulating Tumour Stem Cells (CTSCs).
A new market study of cancer Molecular Diagnostics is published this month by Biopharm Reports. This study, which involved the participation of 596 cancer physicians and research scientists, investigated the use of different molecular techniques, their applications, as well as molecular biomarkers and other key areas. Findings show that while cancer diagnostics is dominated by techniques such as immunohistochemistry, imaging and PCR methodologies, this study found that the most rapidly developing diagnostic areas are Next-Generation Sequencing (NGS), Mass Spectrometry (MS), Microarray and the study of Circulating Tumour Cells (CTCs) and Cancer Stem Cells (CSCs).
Biopharm Reports carries out market studies of techniques, methods, and instrumentation used in life science and clinical laboratories. These are conducted through specialist groups of experienced end-users and practitioners, and therefore findings are based on 'real world' market data.